As it advances through phase 2 trials, hopes are high for this innovative therapy in addressing critical unmet needs in mental health. Achieveing this and meeting US FDA requirements for safe, chronic dosing, triggers a significant $15 million payment to Nxera (formerly Sosei Group) from Neurocrine. NBI-1117568 is part of a broader portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1, and dual M1/M4 receptor agonists developed by Nxera and progressing under a global collaboration established in 2021 with Neurocrine. Matt Barnes, EVP, president of Nxera Pharma UK and head of R&D, said: “We are delighted that NBI-1117568 has successfully achieved this important safety development milestone. These results will support the safe, long-term use of this novel clinical candidate, which is consistent with a desired product profile for schizophrenia and other neurological diseases where patients often need therapy over many years. “We are extremely pleased at the progress being made under our highly productive partnership with Neurocrine and look forward to reporting further progress and upcoming clinical data readouts, including the top-line Phase 2 data on NBI-1117568, which is expected in the second half of 2024.” Nxera retains rights to develop M1 agonistsM1 agonists in Japan, an aspect emphasized by Barnes. The partnership with NeurocrineNeurocrine aims to address major unmet medical needs in neurological disorders by targeting selective activation of M4 and M1 receptors in the brain, offering potential blockbuster treatments. googletag.cmd.push(function () {
googletag.display('text-ad1');
Through their collaboration, Nxera and Neurocrine said they aim to alleviate suffering and provide innovative treatments for patients with neurological conditions, demonstrating their commitment to advancing neuroscience research and therapeutic solutions.